Lowering prescription drug prices is a laudable focus of the Trump Administration, and the Campaign for Sustainable Rx Pricing (CSRxP) supports several measures put forward by the administration, including getting more generics and biosimilars into the market to spur competition, increasing drug price transparency and cracking down on anti-competitive practices from big pharmaceutical manufacturers. But […]
Three More Congressional Hearings Tackle Big Pharma’s Anti-Competitive Practices This week, the U.S. Senate Special Committee on Aging, U.S. House Ways & Means Subcommittee on Health and U.S. House Judiciary Subcommittee on Antitrust kept up the pace of activity on prescription drug pricing with a series of hearings on the issue. Members of Congress […]
During today’s House Judiciary Subcommittee on Anti-trust hearing on healthcare consolidations – Members of Congress recognized Big Pharma’s continued role in price gouging American patient through patent abuse schemes to hinder generic competition and maintain monopolies over their biggest money makers. Importantly, key members of the committee used the hearing as an opportunity to tout the benefits […]
Big Pharma is able to price gouge patients and avoid accountability. For decades, drug makers have gamed the patent system to block out competition and protect their profits – maintaining monopolies and driving up prices without making improvements to the medications patients need most. Take a look: Of the 100 best selling drugs, […]
Testimony from Seven Drug Makers Showcases Continued Unwillingness to Take Responsibility, Become Part of the Solution On Tuesday, executives from seven of the biggest pharmaceutical companies in the world – including AbbVie, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Sanofi, AstraZeneca and Merck – testified before the Senate Committee on Finance on the crisis of […]
Big Pharma’s True Track Record Is A Hard Pill To Swallow Looking back at Big Pharma’s track record of broken proclamations, pledges and promises, it’s clear drug makers are not committed to turning their rosy rhetoric into reality for struggling American patients. With one in four Americans unable to afford their medications, it’s time Big […]
In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]
By Sarah Gleich Saturday, Feb. 23, 2019 I have had diabetes since I was 5 years old. Like millions of people with diabetes, I rely on insulin 24 hours a day to survive. People like us are fighting for our lives due to the skyrocketing price of insulin. Year after year, the price goes up, […]
In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]
In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record. […]